Some Minorities More Likely to Have Dementia but Less Apt to Signal so on PET Imaging

Why It Matters

If clinicians prioritize amyloid PET findings, Black and Hispanic patients may be under‑diagnosed and miss therapeutic or trial opportunities, widening existing health inequities.

Key Takeaways

• Black and Hispanic patients 28% and 22% less likely amyloid‑positive
• PET‑negative results may limit treatment and trial access for minorities
• Higher amyloid odds in distressed neighborhoods versus prosperous areas
• Black and Hispanic participants present at dementia stage more often
• Study underscores need for non‑amyloid dementia diagnostics

Pulse Analysis

The disparity in dementia outcomes among racial and ethnic groups has long been documented, but this study adds a crucial imaging dimension. Amyloid PET scans, the gold standard for detecting Alzheimer’s‑related plaques, are increasingly used to guide treatment decisions and clinical trial enrollment. By showing that Black and Hispanic individuals are markedly less likely to light up on these scans, the research suggests that a substantial subset of minority patients may have non‑amyloid forms of dementia that go unnoticed when clinicians rely solely on PET results. This diagnostic blind spot can delay appropriate care and skew trial demographics, reinforcing systemic inequities.

Beyond biology, the investigation highlights the role of socioeconomic context. Participants living in “distressed” zip codes—measured by the Area Deprivation Index—exhibited a 40% increase in amyloid positivity compared with those in affluent neighborhoods, while those in “comfortable” areas still faced a 22% rise. The link between higher amyloid burden and disadvantaged environments points to intersecting factors such as chronic stress, limited access to preventive health services, and environmental exposures. Moreover, the study found that Black and Hispanic patients were more likely to be enrolled in Medicare Advantage plans, a proxy for complex access‑to‑care barriers that may further impede timely diagnosis.

For policymakers and clinicians, the findings call for a broader diagnostic toolkit that does not over‑rely on amyloid imaging. Incorporating biomarkers for tau, vascular contributions, and neuroinflammation, alongside comprehensive neuropsychological assessments, could capture the full spectrum of dementia etiologies across diverse populations. Health systems should also invest in community‑based outreach and culturally tailored screening programs to ensure early detection. As the U.S. grapples with an aging population, equitable dementia care will depend on moving beyond a one‑size‑fits‑all imaging paradigm toward inclusive, multimodal evaluation strategies.